A Phase I/IIa clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that the first gene regulation treatment for epilepsy is safe and well tolerated ...

Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients ...

Musunuri projected, "We are on track to begin the rolling BLA submission in the third quarter of 2026," with OCU400 commercialization anticipated in 2027. For OCU410ST, top line Phase II/III data is ...

Clinical trials can vary in length depending on several factors. Here's what you need to know about how long clinical trials last.

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition ...

A new computational method allows modern atomic models to learn from experimental thermodynamic data, according to a ...

Compugen Ltd. (NASDAQ: CGEN) Q4 2025 Earnings Call Transcript March 2, 2026 Compugen Ltd. beats earnings expectations. Reported EPS is $0.6, expectations were $0.05.

Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

Q4 2025 earnings call recap: evorpacept/CD47 biomarker data, ASPEN-09 expansion, ALX2004 updates, and $150M raise—read now.

Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...